ZYVERSA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 29 shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 29.00 shares, a 222.22% increase year-over-year.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 67.00 shares, a 148.15% increase year-over-year.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 143.00 shares.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 219.00 shares, a 65.29% decline from fiscal 2024.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 631.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | 29.00 shares 10-Q · filed 2026-05-13 | 96.00 shares derived: sum of 2 quarters · filed 2026-05-13 | 96.00 shares derived: sum of 3 quarters · filed 2026-05-13 | 239.00 shares derived: sum of 4 quarters · filed 2026-05-13 | |
| 2025-12-31 | 67.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 67.00 shares derived: sum of 2 quarters · filed 2026-03-31 | 210.00 shares derived: sum of 3 quarters · filed 2026-03-31 | 219.00 shares 10-K · filed 2026-03-31 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | 143.00 shares derived: sum of 2 quarters · filed 2025-11-19 | 152.00 shares 10-Q · filed 2025-11-19 | 179.00 shares derived: sum of 4 quarters · filed 2025-11-19 | |
| 2025-06-30 | 143.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 152.00 shares 10-Q · filed 2025-08-13 | 179.00 shares derived: sum of 3 quarters · filed 2025-08-13 | 211.00 shares derived: sum of 4 quarters · filed 2025-08-13 | |
| 2025-03-31 | 9.00 shares 10-Q · filed 2025-05-12 | 36.00 shares derived: sum of 2 quarters · filed 2025-05-12 | 68.00 shares derived: sum of 3 quarters · filed 2025-05-12 | ||
| 2024-12-31 | 27.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 59.00 shares derived: sum of 2 quarters · filed 2025-03-27 | 631.00 shares 10-K · filed 2025-03-27 | ||
| 2024-09-30 | 32.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 604.00 shares 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | 572.00 shares 10-Q · filed 2024-08-09 | ||||
| 2022-01-06 | 214.46K shares 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |